Skip to main content
. 2021 Oct 25;8:736042. doi: 10.3389/fcvm.2021.736042

Figure 3.

Figure 3

Kaplan–Meier analyses of the atrial fibrillation (AF) recurrence-free survival rate in the cohort 1 (the main cohort) (n = 3,239; A,B) and in the cohort 2 (the external validation cohort) (n = 360, C,D). AAD, antiarrhythmic drugs.